Lazard Asset Management
CORT icon

Lazard Asset Management’s Corcept Therapeutics CORT Stock Holding History

Lazard Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$803K Buy
9,232
+953
+12% +$57.5K ﹤0.01% 1283
2026
Q1 		$334K Buy
8,279
+1,274
+18% +$47.6K ﹤0.01% 1477
2025
Q4 		$244K Sell
7,005
-26
-0.4% -$2.04K ﹤0.01% 1590
2025
Q3 		$584K Sell
7,031
-181
-3% -$13.1K ﹤0.01% 1304
2025
Q2 		$528K Sell
7,212
-12,735
-64% -$923K ﹤0.01% 1479
2025
Q1 		$2.28M Sell
19,947
-53
-0.3% -$3.23K ﹤0.01% 930
2024
Q4 		$1.01M Buy
20,000
+1,410
+8% +$73.9K ﹤0.01% 1150
2024
Q3 		$859K Sell
18,590
-45
-0.2% -$1.6K ﹤0.01% 1148
2024
Q2 		$605K Sell
18,635
-1,866
-9% -$51.1K ﹤0.01% 1132
2024
Q1 		$516K Sell
20,501
-1,133
-5% -$26.8K ﹤0.01% 1048
2023
Q4 		$702K Sell
21,634
-6,771
-24% -$186K ﹤0.01% 1027
2023
Q3 		$773K Buy
28,405
+27,140
+2,145% +$785K ﹤0.01% 1032
2023
Q2 		$28K Buy
+1,265
New +$29.1K ﹤0.01% 2022
2023
Q1 		– Sell
-2,657
Closed -$53K – 2335
2022
Q4 		$53K Buy
2,657
+321
+14% +$8.05K ﹤0.01% 1784
2022
Q3 		$59K Sell
2,336
-194
-8% -$5.19K ﹤0.01% 1720
2022
Q2 		$60K Buy
2,530
+2,424
+2,287% +$52.8K ﹤0.01% 1728
2022
Q1 		$2K Sell
106
-3,263
-97% -$69.4K ﹤0.01% 2241
2021
Q4 		$66K Sell
3,369
-61,418
-95% -$1.25M ﹤0.01% 1616
2021
Q3 		$1.27M Buy
64,787
+61,490
+1,865% +$1.29M ﹤0.01% 1003
2021
Q2 		$72K Hold
3,297
– – ﹤0.01% 1444
2021
Q1 		$78K Hold
3,297
– – ﹤0.01% 1265
2020
Q4 		$86K Sell
3,297
-753
-19% -$15.9K ﹤0.01% 1217
2020
Q3 		$70K Buy
4,050
+2,225
+122% +$35.5K ﹤0.01% 1093
2020
Q2 		$30K Sell
1,825
-2,592
-59% -$36.4K ﹤0.01% 1364
2020
Q1 		$52K Buy
4,417
+4,168
+1,674% +$51.6K ﹤0.01% 1159
2019
Q4 		$3K Buy
+249
New +$3.47K ﹤0.01% 1451
2018
Q1 		– Sell
-17,422
Closed -$314K – 1055
2017
Q4 		$314K Buy
+17,422
New +$316K ﹤0.01% 834

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lazard Asset Management's CORT Position: Q2 2026 in Review

Lazard Asset Management increased its Corcept Therapeutics (CORT) stake by 12% in Q2 2026, buying an estimated $57.5K and bringing the position to 9,232 shares worth $803K. The position accounts for ﹤0.01% of the portfolio, ranked #1283.

Lazard Asset Management first reported a position in CORT in Q4 2017 and has held it in 27 quarters since. The position peaked at $2.28M in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Lazard Asset Management held 9,232 shares of Corcept Therapeutics worth $803K as of Q2 2026.
  • Lazard Asset Management bought 953 Corcept Therapeutics shares in Q2 2026, an estimated $57.5K.
  • Corcept Therapeutics made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1283 holding.
  • Lazard Asset Management first reported a position in Corcept Therapeutics in Q4 2017 and has held it in 27 quarters since.
  • Lazard Asset Management's Corcept Therapeutics position peaked at $2.28M in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.